Clinical Trial Update: A Study to Evaluate Renal Safety of Intravenous Ibandronate (Bondronat) in Participants With Metastatic Bone Disease Due to Breast Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial assessing renal safety of intravenous ibandronate (Bondronat) in patients with metastatic bone disease due to breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bone Metastases
• Breast Cancer

Drugs mentioned

• Bondronat (ibandronate) (ibandronate)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Pain; Bone Neoplasms; Neoplasm Metastasis | Phase 3 | Status: COMPLETED